Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2377-2383

  Klammt, Sebastian ^a   Wojak, Hans Joachim ^a   Mitzner, Andrea ^a   Koball, Sebastian ^a   Rychly, Joachim ^a   Reisinger, Emil C ^a   Mitzner, Steffen ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin; Albumin binding; Chronic kidney disease; Indoxyl sulphate; Uraemic toxins

Indexed keywords

ALBUMIN; INDICAN; UREMIC TOXIN;

ALBUMIN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; FEMALE; FILTRATION; FLUORESCENCE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PLASMA; PRIORITY JOURNAL; PROTEIN FUNCTION; URINE VOLUME;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; FLUORESCENT DYES; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; SERUM ALBUMIN; TOXINS, BIOLOGICAL; UREMIA;

EID: 84861848600     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr616     Document Type: Article

References (58)

1. Verbeeck RK,Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65: 757-773
2. Mingrone G, De Smet R, Greco AV et al. Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin. Clin Chim Acta 1997; 260: 27-34
3. Meijers BK, Bammens B, Verbeke K et al. A review of albumin binding in CKD. Am J Kidney Dis 2008; 51: 839-850
4. Nishio T, Takamura N, Nishii R et al. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition. Nephrol Dial Transplant 2008; 23: 2304-2310
5. de Mutsert R, Grootendorst DC, Indemans F et al. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 2009; 19: 127-135
6. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 2010; 21: 223-230
7. Mera K, Anraku M, Kitamura K et al. The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005; 334: 1322-1328
8. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509
9. LimPS, Cheng YM,Yang SM. Impairments of the biological properties of serum albumin in patients on haemodialysis. Nephrology (Carlton) 2007; 12: 18-24
10. Terawaki H, Era S, Nakayama M et al. Decrease in reduced-form albumin among chronic kidney disease patients: new insights in cardiovascular complications. Ther Apher Dial 2011; 15: 156-160
11. Anraku M, Takeuchi K, Watanabe H et al. Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. J Pharm Sci 2011; 100: 3968-3976
12. Nakajou K, Watanabe H, Kragh-Hansen U et al. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 2003; 1623: 88-97
13. Dengler TJ, Robertz-VaupelGM, Dengler HJ.Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992; 43: 491-499
14. Watanabe H, Miyamoto Y, Otagiri M et al. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci 2011; 100: 3682-3695
15. Wu IW, Hsu KH, Lee CC et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2010; 26: 938-947
16. Glassock RJ. Uremic toxins: what are they? An integrated overview of pathobiology and classification. J Ren Nutr 2008; 18: 2-6
17. Jourde-Chiche N, Dou L, Cerini C et al. Protein-bound toxins-update 2009. Semin Dial 2009; 22: 334-339
18. Vanholder R, De SR, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
19. Vanholder R, Baurmeister U, Brunet P et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19: 863-870
20. Meijers BK, Loor HD, Bammens B et al. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1932-1938
21. Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26: 759-761
22. Enomoto A, Takeda M, Tojo A et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711-1720
23. Kawakami T, Inagi R, Wada T et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010; 299: F568-F576
24. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558
25. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract 2009; 83: 220-226
26. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14: 207-212
27. Fujii H, Nakai K, Fukagawa M. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial 2011; 15: 125-128
28. Miyamoto Y, Watanabe H, OtagiriMet al. New insight into the redox properties of uremic solute indoxyl sulfate as a pro-and anti-oxidant. Ther Apher Dial 2011; 15: 129-131
29. Klammt S, Stange J, Mitzner S et al. Albumin Binding Capacity (ABiC) and binding of Diazepam is impaired by commercially available albumin preparation and can be avoided by single pass deligandization [Abstract]. Eur J Clin Pharmacol 2005; 61: 710
30. Klammt S, Brinkmann B, Mitzner SR et al. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol 2001; 39: 24-27
31. Klammt S, Mitzner SR, Stange J et al. Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis. Liver Transpl 2008; 14: 1333-1339
32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
33. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann InternMed 2006; 145: 247-254
34. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
35. Klammt S, Mitzner S, Stange J et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 2007; 19: 257-263
36. Niwa T, Takeda N, Tatematsu A et al. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 1988; 34: 2264-2267
37. Owen WF Jr., Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006
38. Obialo CI, Okonofua EC, Nzerue MC et al. Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int 1999; 56: 1058-1063
39. Becher E, Litzner S, Doenecke F. Das Konzentrationsverhältnis aromatischer Substanzen zwischen Serum und Harn bei Nierengesunden und Nierenkranken. Münchner Medizinische Wochenschrift 1927; 39: 1656-1657
40. Bowmer CJ, Lindup WE. Effect of endogenous metabolites on the binding of o-methyl red to human serum albumin. Br J Pharmacol 1976; 58: 283P-284P
41. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468-475
42. Mitzner SR, Stange J, Klammt S et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-S82
43. Muting D. Studies on the pathogenesis of uremia. Comparative determinations of glucuronic acid, indican, free and bound phenols in the serum, cerebrospinal fluid, and urine of renal diseases with and without uremia. Clin Chim Acta 1965; 12: 551-554
44. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975; 11: 824-832
45. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007; 151: 580-590
46. Matsuyama Y, Terawaki H, Terada T et al. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 2009; 13: 308-315
47. Shimoishi K, Anraku M, Kitamura K et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 2007; 24: 1283-1289
48. Tesseromatis C, Alevizou A. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet 2008; 33: 225-230
49. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999; 123: 822-823
50. De SR, Van KJ, Van VB et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478
51. Liabeuf S, Barreto DV, Barreto FC et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
52. Lin CJ, Wu CJ, Pan CF et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693-3700
53. Locatelli F, Martin-Malo A, Hannedouche T et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654
54. Vanholder R, Smet RD, Glorieux G et al. Survival of hemodialysis patients and uremic toxin removal. Artif Organs 2003; 27: 218-223
55. Bammens B, Evenepoel P, Verbeke K et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243
56. Russo LM, Sandoval RM, Campos SB et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20: 489-494
57. Comper WD, Hilliard LM, Nikolic-Paterson DJ et al. Diseasedependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295: F1589-F1600
58. Keller E, Beeser H, Peter HH et al. Comparison of fresh frozen plasma with a standardized serum protein solution following therapeutic plasma exchange in patients with autoimmune disease: a prospective controlled clinical trial. Ther Apher 2000; 4: 332-337